跳至主要内容
临床试验/CTRI/2018/01/011393
CTRI/2018/01/011393招募中4 期

Comparative evaluation of efficacy & safety of Lurasidone & Olanzapine in patients of Schizophrenia:A Randomized,Parallel,Open-label, Clinical study

Dr Bhagyashree Mohod0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patient of schizophrenia who is consulting first time to psychiatrist for the complaints
  • 2. PANSS (positive and negative syndrome scale) score more than or equal to 80
  • 3. Patient willing to give written informed consent.

排除标准

  • Exclusion criteria :-
  • 1)Pregnant, Nursing Women and children
  • 2)Patients requiring other psychotropic medications, central nervous system active drugs
  • 3)Patient with neurologic disorders (dementia, seizures, stroke), obesity , serious or not stabilized organic disorders (neoplasia, cardiovascular, pulmonary, uncontrolled type 1 or 2 diabetes)
  • 4)Patients with any other psychiatric disorders
  • 5)Abnormal renal/hepatic function

研究者

发起方
Dr Bhagyashree Mohod

相似试验